Pocobelli Gaia, Newcomb Polly A, Trentham-Dietz Amy, Titus-Ernstoff Linda, Hampton John M, Egan Kathleen M
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Cancer. 2008 Jan 1;112(1):27-33. doi: 10.1002/cncr.23129.
Findings that statins inhibited the proliferation of breast cancer cells in vitro and in rodents have raised interest in whether the use of statins might decrease a woman's risk of developing breast cancer. We analyzed data from a population-based case-control study to evaluate the association between the use of statins and breast cancer risk.
Cases of incident invasive breast cancer in women 50 years of age or older and diagnosed from 1995-2001 were identified from population-based cancer registries in Wisconsin, Massachusetts, and New Hampshire. Controls were randomly selected, within each state, from lists of licensed drivers and Medicare beneficiaries. Information on the use of statins and other breast cancer risk factors was ascertained from structured telephone interviews.
Overall, breast cancer cases were not more likely than controls to have ever used statins. Ever use of lipophilic statins as a group (simvastatin, lovastatin, and fluvastatin) and ever use of the hydrophilic statin pravastatin were also not associated with breast cancer risk. Ever use of fluvastatin was associated with a decreased risk of breast cancer (odds ratio [OR], 0.5; 95% confidence interval, 0.3-0.8) but the magnitude of the ORs did not vary across categories of duration of use.
The use of statins overall was not associated with breast cancer risk.
他汀类药物在体外实验和啮齿动物实验中可抑制乳腺癌细胞增殖，这一发现引发了人们对于他汀类药物的使用是否能降低女性患乳腺癌风险的关注。我们分析了一项基于人群的病例对照研究的数据，以评估他汀类药物的使用与乳腺癌风险之间的关联。
从威斯康星州、马萨诸塞州和新罕布什尔州基于人群的癌症登记处识别出1995年至2001年间确诊的50岁及以上女性浸润性乳腺癌新发病例。在每个州内，从持照驾驶员名单和医疗保险受益人名单中随机选取对照。通过结构化电话访谈确定他汀类药物使用情况及其他乳腺癌风险因素的信息。
总体而言，乳腺癌病例既往使用他汀类药物的可能性并不高于对照。作为一个整体，既往使用亲脂性他汀类药物（辛伐他汀、洛伐他汀和氟伐他汀）以及既往使用亲水性他汀类药物普伐他汀也与乳腺癌风险无关。既往使用氟伐他汀与乳腺癌风险降低相关（比值比[OR]，0.5；95%置信区间，0.3 - 0.8），但OR值的大小在不同使用时长类别中并无差异。
总体而言，他汀类药物的使用与乳腺癌风险无关。
